RANI Therapeutics

RANI · Nasdaq · United States

Share price · RANI

$0.65-0.18 (-21.48%) 3M

close as of 2026-11-18 · 24h delayed · vol 1.2M (2.3x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when RANI's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 18 Nov 2026+15.9%

    Nothing announced by RANI that day or the session before.

  2. 22 Jul 2026+29.8%

    Nothing announced by RANI that day or the session before.

  3. 7 Jul 2026-10.6%

    Nothing announced by RANI that day or the session before.

  4. 26 May 2026-12.1%
  5. 20 May 2026+23.3%

    Nothing announced by RANI that day or the session before.

  6. 11 May 2026+10.8%

    Nothing announced by RANI that day or the session before.

  7. 15 Apr 2026+14.7%

    Nothing announced by RANI that day or the session before.

  8. 1 Apr 2026+9.5%

    Nothing announced by RANI that day or the session before.

  9. 27 Mar 2026-24.9%
  10. 18 Mar 2026-9.2%

    Nothing announced by RANI that day or the session before.

Share of unusual movement by asset

For each asset, the share of RANI's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Other company news (earnings, financing, releases naming no asset)—75%
Sessions with no dated event—25%

No dated announcements about its assets since 2 Jul 2024.

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
0Diseases
Showing 1 of 1 assets
Target & Modality
Phase 1
GLP-1/GLP-2 receptor (dual)
Indication not yet linked

Discontinued programmes (1)

Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$1.7M$6.0M$3.8M$7.7M-$7.8M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$1.7M$5.0M$5.1M$7.4M-$9.0M operating cash flowreport ↗
2026-Q1$1.7M$5.2M$9.8M$7.0M-$6.5M operating cash flowreport ↗
2025-Q3$0$3.2M$4.6M$5.4M-$5.1M operating cash flowreport ↗
2025-Q2$0$5.5M$11M$6.7M-$5.8M operating cash flowreport ↗
2025-Q1$0.2M$6.6M$11M$7.3M-$8.2M operating cash flowreport ↗
2024-Q3$0$6.2M$4.8M$6.8M-$8.4M operating cash flowreport ↗
2024-Q2$0$6.1M$5.0M$6.8M-$9.0M operating cash flowreport ↗
2024-Q1$0$7.6M$7.4M$7.5M-$9.4M operating cash flowreport ↗
2023-Q3—$11M$5.5M$9.2M-$14M operating cash flowreport ↗
2023-Q2—$11M$8.1M$9.3M-$12M operating cash flowreport ↗
2023-Q1—$9.7M$19M$8.4M-$12M operating cash flowreport ↗
2022-Q3$0$9.1M$28M$8.0M-$12M operating cash flowreport ↗
2022-Q2$0$9.5M$97M$7.6M-$10M operating cash flowreport ↗
2022-Q1—$7.6M$108M$6.2M-$9.4M operating cash flowreport ↗
2021-Q3$0$12M$130M$3.1M-$11M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$1.6M$20M$19M$7.4M-$19M operating cash flowreport ↗

For FY2025, RANI Therapeutics reported revenue of $1.63M, up 58.3% YoY, with R&D spend of $20.2M, down 24.3% YoY. Cash and equivalents were $18.82M, and the company reported a net loss of $29.67M and quarterly net burn of $29.67M.

Operationally, RANI announced an up-to-$1.085B collaboration with Chugai, completed a $60.3M oversubscribed private placement, and repaid all outstanding debt. It reported preclinical data supporting oral delivery of semaglutide via RaniPill and bioequivalence of RT-114, and initiated a Phase 1 study of RT-114 for obesity in collaboration with ProGen. Management expects existing cash, including an expected Chugai milestone payment, to fund operations into the fourth quarter of 2027 and anticipates higher R&D expenses in future periods.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$1.0M$27M$4.3M$7.5M-$36M operating cash flowreport ↗
2023-FY$0$40M$6.4M$8.5M-$51M operating cash flowreport ↗
2022-FY$0$37M$28M+ $99M short-term inv.$7.7M-$47M operating cash flowreport ↗
2021-FY$2.7M$26M$118M$2.1M-$32M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 2 purchases ($50K), 1 sale ($301). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-09-27Javadi Alireza · Chief Technical OfficerTax withholding309$0.76$235Form 4
2026-09-27Imran Talat · director, Chief Executive OfficerTax withholding7,928$0.76$6KForm 4
2026-08-03Gilson Michelle · directorAward / grant (derivative)247,200——Form 4
2026-07-21IMRAN MIR A · director, 10% ownerOpen-market purchase36,000$0.69$25KForm 4
2026-07-17Maestas Nicholas · Chief Financial OfficerAward / grant (derivative)2,000,000——Form 4
2026-07-17Imran Talat · director, Chief Executive OfficerOpen-market purchase35,000$0.72$25KForm 4
2026-06-27Javadi Alireza · Chief Technical OfficerTax withholding309$0.74$229Form 4
2026-06-27Imran Talat · director, Chief Executive OfficerTax withholding7,927$0.74$6KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 73 reporting institutions held 42.7M shares ($31.2M, 34.5% of shares outstanding).

#InstitutionSharesValue
1RA CAPITAL MANAGEMENT, L.P.8,500,000$6.2M
2SAMSARA BIOCAPITAL, LLC8,500,000$6.2M
3AWM Investment Company, Inc.6,500,000$4.8M
4VANGUARD CAPITAL MANAGEMENT LLC4,622,567$3.4M
5SymBiosis Capital Partners, LLC3,667,585$2.7M
6Longaeva Partners L.P.2,329,459$1.7M
7Siren, L.L.C.2,000,000$1.5M
8GEODE CAPITAL MANAGEMENT, LLC903,298$664K
9BlackRock, Inc.556,889$409K
10Nan Fung Group Holdings Ltd493,584$363K
11683 Capital Management, LLC487,168$358K
12VANGUARD FIDUCIARY TRUST CO455,050$334K
13MILLENNIUM MANAGEMENT LLC405,669$298K
14STATE STREET CORP373,142$274K
15UNITED SERVICES AUTOMOBILE ASSOCIATION302,743$222K